Steering committee
A consortium of doctors, researchers, biologists, anatomopathologists, scientists, manufacturers, drug specialists and artificial intelligence specialists has been set up to develop new diagnostic, prognostic and therapeutic tools for cutaneous T lymphomas, in order to improve the management of patients suffering from these diseases.
The consortium comprises academic partners, including Université Paris Cité, the coordinating institution, and industrial partners and associations.
© Part of the RHU SPRINT team at the Pre-Kick-Off Meeting. Credits : RHU SPRINT.
Consortium members
Prof. Martine BAGOT, Dermatologist
Cutaneous lymphoma KOL. Lacutamab (IPH4102), jointly developed, is currently undergoing an international Phase 2 trial.
Prof. Maxime BATTISTELLA, Pathologist
Expert member of EORTC, Cutaneous Lymphoma Group & International Society of Cutaneous Lymphomas
Prof. Marie BEYLOT-BARRY, Head of Dermatology, Bordeaux University Hospital
Co-Director, INSERM BRIC Team 5, General Secretary, GFELC
Board of Directors, International Society of Cutaneous Lymphomas
Dr. Lucie BIARD, Biostatistics
Specialist in early-phase clinical trial design INCa-certified data processing center
Prof. Stéphane DALLE, Head of Dermatology Department, Hospices Civils Lyon
Co-leader of the Qualitop Cancer Research Center research team, coordinating team for the European H2020 project
Prof. Adèle de MASSON, Project Coordinator
Dermatologist, Coordinator of the French National Cutaneous Lymphoma Network (INCa)
Prof. Isabelle DURAND-ZALESKI, Medical Economics
Head of the AP-HP clinical research unit on health economics and health services
Prof. Nikos PARAGIOS, AI-precision medicine
Professor Emeritus of Mathematics, CEO of TheraPanacea, world-renowned expert in artificial intelligence
Dr. Stephan SCHANN, Immuno-oncology, drug development
Chief Scientific Officer of Domain Therapeutics, an R&D expert in next-generation immunotherapies and leader of Domain’s proprietary programmes targeting GPCRs.
Read more
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.